moement iorer moment pain & palliative care in movement

MAY 2021 PRACTICAL NEUROLOGY 63

M O V E M E N T D I S O R D E R S M O M E N T

Although there is no disease-modifying treatment approved for Parkinson disease (PD) yet, symptomatic treatment of motor symptoms has improved dramatically with advances in

pharmacotherapy and neuromodulation. Compared with motor symptoms, however, nonmotor symptoms collectively have a larger effect on health-related quality of life (HRQoL) measures.1 Pain is a frequently underrecog-nized nonmotor symptom, despite being quite

common with reported prevalence of up to 85% in people with PD. As with other nonmotor symptoms, pain tends to worsen as motor symptoms do.2-7 Clinicians can address the underdiagnosis and undertreatment of pain by screening for the 5 categories of PD-related pain (Table)8 Pain is also com-mon in other neurodegenerative movement disorders.

In advanced PD, individuals may be more sensitive to medi-cation side effects, particularly as polypharmacy becomes more common with different medication classes complexly layered to maximize motor on-time while attempting to reduce levodopa-induced dyskinesias. Special attention must

be paid to cognition as well, because people with advanced PD are susceptible to delirium. Additionally, if significant hypophonia, dysarthria, or cognitive impairment are present, it may be difficult to understand the precise location, nature, or etiology of pain. This complexity may necessitate a broader diagnostic approach (eg, exam with gentle palpation, uri-nalysis, basic labs, or plain films) and sometimes empiric pain treatment with nonnarcotic analgesics. Exercise and therapy are a mainstay of PD care and continue to be important in advanced PD, even if only for maintaining flexibility and pre-venting painful contractures.9 The concept of neuropalliative care related to movement disorders and how neurologists can help optimize quality of life and alleviate suffering becomes ever more important as PD progresses.

Categories of Pain in Parkinson DiseaseMusculoskeletal Pain

Pain in people with PD most commonly presents as muscu-loskeletal, frequently related to secondary spine or joint arthro-sis and amplified by akinesia, rigidity, and dystonia. There is not always a correlation to motor symptom severity, however. Pain can manifest at any stage of PD, including premotor and early stages. For example, “shoulder-arm” syndrome can mimic rota-

Pain & Palliative Care in Movement DisordersPain is underrecognized and undertreated in movement disorders and can be addressed with screening, treatment, and a palliative care approach.By Alissa Kasunich MD; Camilla Kilbane MD; and Robert Wiggins, MD

TABLE. THE 5 CATEGORIES OF PARKINSON DISEASE-RELATED PAINCategory Frequency Description Examples

Musculoskeletal 70%3,13 Affecting joints, tendons, or muscles Frozen shoulder, camptocormia, pisa syndrome, striatal hand

Neuropathic 10%-20%3 Radiculopathy, neuropathy Radiculopathy, small fiber neuropathy, large fiber neuropathy

Dystonic 40%13 Twisting, pulling, or cramping sensation (may be dependent on dopamine levels)

Toe curling, foot inversion, blepharospasm, anterocollis

Akathitic 45%16 Sense of restlessness, urge to move Generalized, restless legs syndrome

Central 10%4-40%13 Somatosensory, autonomic, or emotional sensations related to dopamine deficiency

Oral, genital and rectal paresthesia, formications, abdominal pain, coat-hanger pain, depression

aPeople with Parkinson disease (PD) may have more than 1 category of PD-related pain.

64 PRACTICAL NEUROLOGY MAY 2021


tor cuff injury masking early rigidity and bradykinesia.10 People with PD also have a higher rate of osteoporosis,

increasing their risk of fractures, immobility, and pain.10 Osteoarthritic joint pain is also common in PD and tends to increase during “off” medication periods. Joint pain can also be exacerbated by comorbid dystonia. For example, camp-tocormia and Pisa syndrome are thought to be dystonic phenomena associated with musculoskeletal pathology.10 It is important to treat these concomitant factors to prevent these postures from becoming fixed.

Musculoskeletal pain in PD can masquerade as primary rheumatologic or orthopedic conditions. A striatal hand may present with features suggestive of rheumatoid arthritis (eg, ulnar deviation of the metacarpophalangeal [MCP] joints or Dupuytren contracture with flexion of MCP joints).3,11 Careful examination revealing symptoms predominantly ipsilateral to PD should prompt the treatment of motor symptoms, before referral for rheumatologic workup or surgery.

Neuropathic PainPostural changes and skeletal deformities can exert pres-

sure on neural foramina, which can lead to radiculopathy. Careful examination of muscle power, reflexes, and sensation may reveal a motor decline secondary to neuromuscular issues rather than motor symptom progression. In these situations, physical therapy rather than up-titration of dopa-minergic medications may be most appropriate.

Peripheral neuropathy in PD can present as a small fiber neuropathy because of the accumulation of Lewy body pathology (LBP) in autonomic and nociceptive nerve fibers.12 Additionally, people with PD have a higher preva-lence of large fiber neuropathy, possibly from levodopa use. Levodopa catabolism can result in overproduction of homo-cysteine and methylmalonic acid, depleting the cofactor B12 and causing neuropathy.13 Neuropathy is slowly progressive, usually, but can be subacute in those with PD being treated with levodopa-carbidopa intestinal gel. Prospective, random-ized clinical trials are required to clarify the role of vitamin B group supplementation in PD-associated neuropathy.13

Dystonic PainDystonic pain can be dopamine-dependent or -inde-

pendent. Prior to PD diagnosis, dopamine-independent dystonia (eg, kinesiogenic foot dystonia) after exercise may be reported by individuals with early-onset PD, associated with parkin.3,14 Dopamine-dependent dystonia is related to levodopa-dosing schedules and can be more difficult to manage in advanced PD with oral medications alone, because of worsening motor fluctuations and a narrowing therapeutic window. Toe curling and foot inversion occur in evenings or early mornings when the last dose of levodopa has fully worn off and may be described by patients as a

“charley horse” or muscle spasm. Limb dystonia, blepharo-spasm, or cervical dystonia are also related to peak dose or diphasic motor fluctuations.14 Careful attention to the tim-ing of dystonia in relation to a dose of levodopa is crucial to treat dopamine-dependent dystonia.

Akathitic painAkathisia is a sensation of restlessness or discontent that

can occur anywhere in the body at any time of day and is related to levodopa fluctuations in about 50% of patients. Individuals may have an inability to sit still that is partially suppressible but can be distressing in social situations that require prolonged sitting.8,15 Difficulty sitting still can be mistaken for anxiety or dyskinesia, resulting in unnecessary medication additions or reductions.

Akathisia should not be confused with restless legs syndrome (RLS), which is specifically an urge to move the legs that occurs most frequently at night. Although RLS is common in PD, it also occurs in people with neuropathy and iron-deficiency anemia, and a clear association with PD is unproven.3,16

Central PainCentral pain occurs during wearing-off and off periods

and responds to dopaminergic medications, suggesting a relationship to dopamine deficiency.4 Examples include formication; oral, genital, and rectal paresthesias; abdominal pain largely caused by constipation; and coat-hanger pain, characterized by a posterior headache and neck pain in the setting of orthostatic hypotension.2,4,6 Because it is a diag-nosis of exclusion, screening for central pain should be done after evaluating for other causes of pain.

In this review, depression is included in this category, con-sidering pathophysiologic similarity to the central pain syn-dromes with dopamine deficiency and altered serotonergic and noradrenergic transmission. Up to 40% of people with PD experience depression as an emotional form of pain that can lower the threshold for other causes of pain.8

Pain in Other Movement DisordersPain is also common in other neurodegenerative move-

ment disorders. Corticobasal degeneration is an atypical parkinsonism and tauopathy in which limb dystonia is pres-ent in over 50% of cases, 42% of which include pain. The upper limb is most often affected, and patients frequently describe hand pain. Multiple system atrophy is an atypical parkinsonism and a-synucleinopathy that causes pain in at least 50% of cases, most commonly in the back, neck, and shoulders, representing the classically described coat-hanger pain in dysautonomia.17 In Huntington disease (HD), chorea can be painful, and there is consideration that striatal atro-phy may contribute to a person’s interpretation of pain.18,19



A recent systematic review found a mean pain prevalence of 41.3% with a range of 10% to 75%, although the same analysis found that pain might be less burdensome for those with HD compared with the general population. This finding could suggest that pain is eclipsed by the severity of other motor and nonmotor symptoms of HD.18

Pathophysiology of PainThe pathophysiology of pain in PD is complex and not

fully understood. For the purposes of this review, a few potential pathways are highlighted given their practical implications for the treatment of PD-related pain (Figure 1).

The anterolateral spinothalamic (ALS) tract relays signals

from skin nociceptors to the primary somatosensory cortex to localize a painful stimulus. The ALS also projects widely to multiple cortical areas via intralaminar thalamic nuclei for higher order pain processing. Additionally, ALS descend-ing collaterals suppress pain via serotoninergic and norad-renergic signaling.12 In PD, the accumulation of Lewy body pathology in several of the aforementioned areas alters pain signaling. Additionally, the basal ganglia are not communi-cating normally with crucial pain-processing cortices includ-ing somatosensory, orbitofrontal, anterior cingulate, and the amygdala (Figure 1), altering pain perception.12

Pain ManagementDespite the high prevalence of pain in PD, only about

50% of people with PD receive pain treatment. Among the commonly used medications, patients report benefit with nonsteroidal anti-inflammatory drugs (NSAIDs), safinamide, and catechol-O-methyltransferase (COMT) inhibitors.2,20 See Figure 2 for treatment of pain by category. For musculo-skeletal pain, first compare the Unified Parkinson’s Disease Rating Scale (UPDRS) score at the current visit with scores from prior visits, because motor symptoms can exacerbate musculoskeletal pain and radiculopathy. In such cases, upti-tration of the PD regimen may provide relief. If the UPDRS in the affected limb is unchanged, consider NSAIDs for pain reduction to facilitate participation in physical therapy.2

Medical marijuana for pain management in PD is a clinical question that comes up often. There is evidence to suggest it may be helpful with primary and secondary pain syndromes, but none of that evidence is specific to treatment of pain in people with PD.

Neuropathy can be treated symptomatically with gaba-pentin and antidepressants, although there are no pharma-cotherapy guidelines for neuropathic pain in PD.2 Screen for and treat any B12 deficiency in people being treated with levodopa.13

For dopamine-dependent dystonia, first optimize the dopaminergic regimen to minimize motor fluctuations. The addition of amantadine or anticholinergics can be helpful. Botulinum toxin injections are an excellent option for focal dystonia3 and other aspects of movement disor-ders.21 There have been mixed results when studied in PD, although many movement disorder specialists target focal off dystonia such as painful toe curling with botulinum toxin injections.21-24 Increased efficacy may occur with ultrasound guided injections.23

In people with dystonia refractory to medication, modula-tion of dysfunctional striato-thalamo-cortical circuits with deep brain stimulation (DBS) is a well-established treatment for reducing painful off dystonia while also decreasing levodo-pa-induced dyskinesias.3,4,12 DBS may also reduce pain in PD independent of its effects on motor symptoms, although pain

Figure 1. Neurodegeneration of pain signaling and processing pathways in Parkinson disease. Lewy body pathology in Parkinson disease and other synucleinopathies interrupts pain signaling and processing pathways, including anterolateral spinothalamic tract and collateral pathways (green) that carry information from nociceptors in the periphery through the reticular formation to periaqueductal gray (PAG) and the cortex and serotonergic and noradrenergic center descending fibers (blue) that modulate the ascending fibers and disrupted striato-thalamo-cortical circuits.

66 PRACTICAL NEUROLOGY MAY 2021


is not a current indication for DBS in PD.25,26 Recent investiga-tion has shown that DBS can improve quality of life even in patients with early motor fluctuations, which is important to keep in mind because surgical risk increases with age.26,27

Akathitic pain in PD may be related to the effects of nigrostriatal dopamine deficiency on mesolimbic dopamine transmission, resembling akathisia seen with dopamine antagonists. Thus, up-titration of dopaminergic medication may help akathitic pain.10,15 RLS should be worked up and treated as it would in people without PD.16

Central pain treatment should start with optimizing dopaminergic medications. The addition of rotigotine or a serotonin-norepinephrine reuptake inhibitor (SNRI) can be effective.2,28 For refractory central pain, DBS has shown ben-efit in some studies.2,29

Palliative CarePeople with neurodegenerative movement disorders

face presently incurable disease with progressive symptoms that threaten to cause suffering and limit independence and quality of life. Even without curative or disease-mod-ifying therapy, however, neurologists can meet patients’ care needs with symptomatic treatment, a focus on quality of life, and a goal of alleviating suffering. This is the basis of a neuropalliative approach.

In PD, nonmotor symptoms, mood, and gait problems are most associated with poor perceived quality of life. Pain and discomfort are the factors most related to impaired qual-ity of life, even in those without advanced disease.30 These symptoms, among others, offer an opportunity to introduce palliative care focused on improving quality of life by treat-ing symptoms, alleviating suffering, and promoting advanced care planning. Although palliative care is often underuti-lized for neurologic diseases including PD,31 palliative care improves quality of life and reduces caregiver burden of PD, alongside providing improvement in motor symptoms.32

Neurologists, patients and caregivers alike are often hesi-tant and misunderstand palliative care, leading to under-utilization. Palliative care is: 1) not equivalent to hospice or end-of-life care; 2) not only for advanced disease; and 3) not a replacement for having a neurologist who provides longi-tudinal care. Specifically, palliative care in neurodegenerative disease may focus on: 1) coping with new diagnoses or an uncertain future; 2) addressing bothersome symptoms such as pain, anxiety, or depression; 3) discussing levels of sup-port needed and place-of-care transitions; 4) advanced-care planning (eg, decisions about resuscitation, artificial nutri-tion, and intubation); 5) appointing decision makers and completing important legal documents; and 6) considering when, where, and how hospice care may be useful.32,33

Figure 2. The first step in many of the categories of Parkinson disease (PD)-related pain is optimization dopaminergic treatment, which alone may provide symptomatic relief. If musculoskeletal, dystonic, akathitic, or central pain does not respond after such optimization, drugs with different mechanisms of action or neuromodulation may be considered. Special considerations for PD-related pain include screening for osteoporosis or vitamin B12, vitamin D, iron, or calcium deficiencies and supplementing vitamins and minerals accord-ingly. Abbreviations: COMT, catechol-O-methyltransferase; NSAIDs, nonsteroidal anti-inflamatory drugs; PT, physical therapy; RLS, restless legs syndrome; SNRIs, selective serotonin-norepinephrine reuptake inhibitors; TCAs, tricyclic antidepressants; UPDRS, Unified Parkinson’s Disease Rating Scale.



Palliative care has a role at every stage of disease and should not be avoided in early stages. Early involvement of palliative care ensures patients’ desires can be heard before they may be unable to express them.33 Specific clinical trig-gers for considering palliative care referral include:

• recurrent falls, infections, or hospitalizations• wwallowing dysfunction or weight loss• cognitive decline• diagnosis of atypical parkinsonism (eg, multisystem

atrophy [MSA], corticobasal degeneration [CBD], or progressive supranuclear palsy [PSP])

Listening closely to a patient’s concerns often reveals opportunities to openly discuss quality of life and suffering and more easily offer a referral to palliative care. In the past, palliative care often has been misunderstood as only help-ing patients die well. Rather, a more accurate understanding (and certainly more hopeful for patients and those who care for them) is that palliative care can help those with neurode-generative movement disorders to live well.34

ConclusionPain is common in people with PD and other movement

disorders. Although the pathophysiology of pain in PD is complex and not fully understood, as with all pain, neuro-degeneration at multiple points in pain-processing path-ways (Figure 1) likely plays a role and can provide targets for intervention. Identifying categories of PD-related pain can guide management (Figure 2). Core aspects of treating pain in PD are the use of exercise and physical therapy, optimi-zation of dopaminergic treatment, and the use of empiric pain treatments as needed. Palliative care at all stages of PD is beneficial for helping people live as well as they can with their disease, providing symptomatic improvement, improving quality of life, and alleviating suffering. n

1. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR; NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399-406.

2. Buhmann C, Kassubek J, Jost WH. Management of pain in Parkinson’s disease. J Parkinsons Dis. 2020;10(s1):S37-S48.3. Ha AD, Jankovic J. Pain in Parkinson’s disease. Mov Disord. 2012;27(4):485-491.4. Young Blood MR, Ferro MM, Munhoz RP, Teive HA, Camargo CH. Classification and characteristics of pain asssociated

with Parkinson’s disease. Parkinsons Dis. 2016;2016:6067132. doi:10.1155/2016/60671325. Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the

modified QUADAS tool. Mov Disord. 2012;27(4):480-484. 6. Buhmann C, Wrobel N, Grashorn W, et al. Pain in Parkinson disease: a cross-sectional survey of its prevalence, specif-

ics, and therapy. J Neurol. 2017;264(4):758-769. 7. Rana AQ, Kabir A, Jesudasan M, Siddiqui I, Khondker S. Pain in Parkinson’s disease: analysis and literature review. Clin

Neurol Neurosurg. 2013;115(11):2313-2317. 8. Ford B. Pain in Parkinson’s disease. Mov Disord. 2010;25(Suppl 1):S98-S103.9. Abbruzzese G, Marchese R, Avanzino L, Pelosin E. Rehabilitation for Parkinson’s disease: current outlook and future

challenges. Parkinsonism Relat Disord. 2016;22(Suppl 1):S60-S64. 10. Rabin ML, Earnhardt MC, Patel A, Ganihong I, Kurlan R. Postural, bone, and joint disorders in Parkinson’s disease.

Mov Disord Clin Pract. 2016;3(6):538-547.11. Spagnolo F, Fichera M, Bucello S, et al. Striatal hand in Parkinson’s disease: the re-evaluation of an old clinical sign.

J Neurol. 2014;261(1):117-120. 12. Tseng MT, Lin CH. Pain in early-stage Parkinson’s disease: implications from clinical features to pathophysiology

mechanisms. J Formos Med Assoc. 2017;116(8):571-581.13. Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa‐induced neuropathy: a systematic

review. Mov Dis Clin Pract. 2019;6(2):96-103. 14. Tolosa E, Compta Y. Dystonia in Parkinson’s disease. J Neurol. 2006;253(Suppl 7):VII7-VII13.15. Comella CL, Goetz CG. Akathisia in Parkinson’s disease. Mov Disord. 1994;9(5):545-549.

16. Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-424.

17. You HY, Wu L, Yang HT, Yang C, Ding XL. A comparison of pain between Parkinson’s disease and multiple system atrophy: a clinical cross-sectional survey. Pain Res Manag. 2019;2019:3150306. doi:10.1155/2019/3150306

18. Sprenger GP, van der Zwaan KF, Roos RAC, Achterberg WP. The prevalence and the burden of pain in patients with Huntington disease: a systematic review and meta-analysis. Pain. 2019;160(4):773-783.

19. Borsook D, Upadhyay J, Chudler EH, Becerra L. A key role of the basal ganglia in pain and analgesia--insights gained through human functional imaging. Mol Pain. 2010;6:27.

20. Qureshi AR, Rana AQ, Malik SH, et al. Comprehensive examination of therapies for pain in Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology. 2018;51(3-4):190-206.

21. Jost WH. Use of botulinum neurotoxin in Parkinson’s disease: a critical appraisal. Toxins (Basel). 2021;13(2):87.22. Anandan C, Jankovic J. Botulinum toxin in movement disorders: an update. Toxins (Basel). 2021;13(1):42.23. Kreisler A, Gerrebout C, Defebvre L, Demondion X. Accuracy of non-guided versus ultrasound-guided injections in

cervical muscles: a cadaver study. J Neurol. 2021;10.1007/s00415-020-10365-w. doi:10.1007/s00415-020-10365-w24. Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16(2):252-257.25. Pellaprat J, Ory-Magne F, Canivet C, et al. Deep brain stimulation of the subthalamic nucleus improves pain in

Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(6):662-664.26. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications.

N Engl J Med. 2013;368(7):610-622. 27. Cury RG, Galhardoni R, Fonoff ET, et al. Effects of deep brain stimulation on pain and other nonmotor symptoms in

Parkinson disease. Neurology. 2014;83(16):1403-1409. 28. Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s

disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660-665. 29. Kim HJ, Paek SH, Kim JY, et al. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J

Neurol. 2008;255(12):1889-1894. 30. Santos García D, de Deus Fonticoba T, Suárez Castro E, et al. Non-motor symptoms burden, mood, and gait problems

are the most significant factors contributing to a poor quality of life in non-demented Parkinson’s disease patients: results from the COPPADIS Study Cohort. Parkinsonism Relat Disord. 2019;66:151-157.

31. Walker RW, Churm D, Dewhurst F, et al. Palliative care in people with idiopathic Parkinson’s disease who die in hospital. BMJ Support Palliat Care. 2014;4(1):64-67.

32. Kluger BM, Miyasaki J, Katz M, et al. Comparison of integrated outpatient palliative care with standard care in patients with Parkinson disease and related disorders: a randomized clinical trial. JAMA Neurol. 2020;77(5):551-560.

33. Ng JSC. Palliative care for Parkinson’s disease. Ann Palliat Med. 2018;7(3):296-303. 34. Bloem BR, Darweesh SKL, Meinders MJ. Palliative programs for persons with parkinsonism-the next frontier. JAMA

Neurol. 2020;77(5):548-550.

Alissa Kasunich MDUniversity Hospitals Cleveland Medical CenterCase Western Reserve UniversityCleveland, OH

Camilla Kilbane MD University Hospitals Cleveland Medical CenterCase Western Reserve UniversityCleveland, OH

Robert Wiggins, MDMovement Disorders FellowDepartment of NeurologyThe Marlene and Paolo Fresco Institute for Parkinson’s and Movement Disorder at NYU Langone HealthNew York, NY

DisclosuresAK, CK, and RW report no disclosures

COLUMN EDITORJill M. Giordano Farmer, DODirector, Parkinson’s Disease and Movement Disorders Program, Global Neuroscience Institute Assistant Professor, Department of NeurologyDrexel University

Philadelphia, PA

moement iorer moment pain & palliative care in movement

Documents